Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025
Management will participate in two upcoming investor healthcare conferences
SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the first quarter 2025.
A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at . To participate in the live conference call via telephone, please register . Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at following the call.
Upcoming Q2 Investor Conferences
Management plans to participate in the following investor healthcare conferences:
- The BofA Securities 2025 Health Care Conference – fireside chat at 3:00 pm EDT on Wednesday, May 14, 2025.
- Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm EDT on Wednesday, June 11, 2025.
Live and archived webcasts of all presentations can be viewed at .
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit .
Investor Contact
Matt Scalo
(801) 584-3532
Media Contact
Kate Schraml
(224) 875-4493
